Estimaciones de analistas de Wall Street para Akebia Therapeutics, Inc. (AKBA): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 7 |
| Mantener | 4 |
| Venta | 1 |
| Venta fuerte | 0 |
| Analistas totales | 12 |
| Calificación media (1-5) | 0.50 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-0.03 | ||
| 2026-08-05 | $-0.02 | $-0.04 | +52.4% |
| 2026-05-07 | $-0.03 | $-0.01 | -200.0% |
| 2026-02-26 | $-0.05 | $-0.03 | -66.7% |
| 2025-11-10 | $0.00 | $-0.06 | +103.3% |
| 2025-08-07 | $0.00 | $-0.02 | +104.6% |
| 2025-05-08 | $0.03 | $-0.03 | +200.0% |
| 2025-03-13 | $-0.10 | $-0.05 | -100.0% |
Ratios de valoración
| Precio / Valor contable | 9.66 |
| EV / EBITDA | -8.53 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $1.5M | $178.0M | $207.7M | $335.0M | $294.6M | $211.7M | $292.5M | $194.6M | $160.2M | $236.2M |
| Coste de Ventas | $115.8M | $617000 | $7.7M | $145.3M | $64.0M | $81.5M | $22.5M | $74.1M | $63.2M | $39.5M |
| Beneficio Bruto | -$114.2M | $177.4M | $200.1M | $189.7M | $230.7M | $130.2M | $270.0M | $120.5M | $97.0M | $196.7M |
| I+D | $115.8M | $230.9M | $291.1M | $323.0M | $218.5M | $147.9M | $166.0M | $63.1M | $37.7M | $62.4M |
| Generales y Administrativos | $22.2M | $27.0M | $87.1M | $149.5M | $154.1M | $174.1M | $138.6M | $100.2M | $106.5M | $107.5M |
| Gastos Operativos | $138.0M | $257.9M | $378.2M | $476.0M | $608.5M | $394.7M | $350.8M | $166.7M | $147.5M | $173.2M |
| Beneficio Operativo | -$136.5M | -$79.9M | -$178.1M | -$286.3M | -$377.8M | -$264.5M | -$80.8M | -$46.3M | -$50.5M | $23.5M |
| EBITDA | -$136.2M | -$76.1M | -$178.1M | -$249.9M | -$139.8M | -$189.9M | $3.1M | -$8.3M | -$13.7M | $21.7M |
| Gastos por Intereses | 0 | 0 | 0 | $1.4M | $8.9M | $19.9M | $15.7M | $6.0M | $18.2M | $24.2M |
| Beneficio Antes de Impuestos | -$135.7M | -$76.9M | -$171.9M | -$286.3M | -$384.8M | -$282.0M | -$94.2M | -$51.9M | -$69.4M | -$3.7M |
| Impuestos | -$901000 | -$2.8M | -$28.3M | -$6.6M | 0 | 0 | 0 | 0 | 0 | $1.6M |
| Beneficio Neto | -$135.7M | -$76.9M | -$171.9M | -$279.7M | -$384.8M | -$282.0M | -$94.2M | -$51.9M | -$69.4M | -$5.3M |
| BPA | $-3.60 | $-1.77 | $-1.47 | $-2.36 | $-2.53 | $-1.48 | $-0.58 | $-0.28 | $-0.33 | $-0.02 |
| BPA Diluido | $-3.60 | $-1.77 | $-1.47 | $-2.36 | $-2.53 | $-1.48 | $-0.58 | $-0.28 | $-0.33 | $-0.02 |
| Acciones en Circulación (Diluidas) | $37.7M | $43.5M | $116.9M | $118.4M | $138.5M | $165.9M | $182.8M | $187.5M | $210.9M | $257.2M |
Precio
| Precio | $0.92 |
| Capitalización | $246M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: CMPX · CRVS · FDMT · GOSS · KALV · OLMA · PRTA
Explorar sector: Healthcare · Biotechnology
Más secciones de AKBA: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones